1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

13 Aug 2024
Admin
News Article

Genova Diagnostics Collaborates with Neurocode to Unveil Blood Test Utilizing P-Tau217 Biomarker

Genova Diagnostics collaborates with Neurocode to unveil blood test utilizing p-Tau217 biomarker for early detection of Alzheimer’s disease

Overview

Genova Diagnostics, a global leader in comprehensive diagnostic testing, offering innovative assessments to provide insights into gut health, nutrition, metabolic function, hormonal health, and more for personalized healthcare, has announced the launch of its groundbreaking Alzheimer’s Assessment, a non-invasive blood test utilizing the p-Tau217 biomarker for early detection of Alzheimer’s disease. This initiative is enabled by a strategic partnership with Neurocode, a leading innovator in neurological diagnostics and research.

About the New Assessment Method

The new Alzheimer’s Assessment is a significant advancement in the early detection of Alzheimer’s disease.
By leveraging the p-Tau217 biomarker, this simple blood test provides highly accurate results that can identify Alzheimer’s disease years before clinical symptoms appear, allowing for early intervention and management of the disease.
The test offers a less invasive alternative to traditional cerebrospinal fluid and imaging tests, making it an accessible and convenient tool in the fight against Alzheimer’s.

Genova Diagnostics for Innovation

Genova Diagnostics has long been at the forefront of diagnostic innovation, providing healthcare practitioners and individuals with the tools they need to make informed decisions about their health.
The collaboration with Neurocode exemplifies Genova’s commitment to advancing medical research and expanding its portfolio of diagnostic solutions.

Words from the CEO: Genova Diagnostics

“Our partnership with Neurocode has enabled us to bring this state-of-the-art Alzheimer’s Assessment to the market,” said Jeff Ledford, CEO of Genova Diagnostics.
“By combining our expertise in laboratory services with Neurocode’s cutting-edge neurological research, we can offer a test that significantly impacts the early diagnosis and treatment of Alzheimer’s disease. This is a significant step forward in our mission to provide innovative, science-based diagnostic services that improve patient outcomes.”

Statement from the Neurocode

“Neurocode is honored to work with Genova in the clinical launch of Alzpath pTau217 assay for accurately detecting amyloid pathology of Alzheimer’s type,” said Hans Frykman, chief science officer of Neurocode.
“Neurocode has performed the most extensive clinical validation in the industry, making our test very trustworthy even for people with very minor memory issues.”

From the CEO: Neurocode

“Offering the pTau217 biomarker through partnership with Genova Diagnostics gives drastic accessibility to a larger segment of people that can now monitor amyloid activity in their brains with a simple blood draw,” said Roopa Reddy, CEO at Neurocode.
“Neurocode is very excited to realize this potential.”

The Alzheimer’s Assessment is available now to healthcare providers. Results include personalized assessments and clinical context for patient care. For more information about the Alzheimer’s Assessment and other diagnostic services offered by Genova Diagnostics.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!